Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parsaclisib”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Large-scale testing (Phase 3)Ended earlyNCT04551053
What this trial is testing

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 177
Testing effectiveness (Phase 2)Study completedNCT02018861
What this trial is testing

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Who this might be right for
B-Cell Malignancies
Incyte Corporation 88
Testing effectiveness (Phase 2)Study completedNCT03126019
What this trial is testing

INCB050465 in Relapsed or Refractory Follicular Lymphoma

Who this might be right for
Lymphoma
Incyte Corporation 126
Early research (Phase 1)Study completedNCT03039114
What this trial is testing

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Who this might be right for
Lymphoma
Incyte Corporation 26
Early research (Phase 1)Ended earlyNCT02559492
What this trial is testing

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Who this might be right for
Solid Tumors
Incyte Corporation 142
Early research (Phase 1)Study completedNCT03688152
What this trial is testing

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Incyte Corporation 9
Testing effectiveness (Phase 2)UnknownNCT05238064
What this trial is testing

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

Who this might be right for
PI3Kδ InhibitorParsaclisibCHOP+1 more
Fudan University 30
Early research (Phase 1)Study completedNCT04831996
What this trial is testing

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Who this might be right for
Advanced Malignancies
Incyte Corporation 48
Large-scale testing (Phase 3)Ended earlyNCT04551066
What this trial is testing

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 252
Testing effectiveness (Phase 2)Study completedNCT03235544
What this trial is testing

INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Who this might be right for
Lymphoma
Incyte Corporation 162
Early research (Phase 1)Study completedNCT03424122
What this trial is testing

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Who this might be right for
B-cell Lymphoma
Incyte Corporation 50
Early research (Phase 1)WithdrawnNCT05867030
What this trial is testing

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Who this might be right for
Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Testing effectiveness (Phase 2)WithdrawnNCT03780166
What this trial is testing

The Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Who this might be right for
Pemphigus Vulgaris
Incyte Corporation
Testing effectiveness (Phase 2)Study completedNCT03538041
What this trial is testing

INCB050465 in Participants With Autoimmune Hemolytic Anemia

Who this might be right for
Autoimmune Hemolytic Anemia
Incyte Corporation 25
Large-scale testing (Phase 3)Ended earlyNCT05073458
What this trial is testing

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Who this might be right for
Warm Autoimmune Hemolytic Anemia (wAIHA)
Incyte Corporation 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT04661007
What this trial is testing

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Who this might be right for
Non Hodgkins LymphomaDiffuse Large B-cell Lymphoma
Incyte Biosciences Japan GK 72
Testing effectiveness (Phase 2)Study completedNCT03627065
What this trial is testing

INCB050465 in Primary Sjögren's Syndrome

Who this might be right for
Primary Sjögren's Syndrome
Incyte Corporation 10
Large-scale testing (Phase 3)WithdrawnNCT04796922
What this trial is testing

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Who this might be right for
Follicular Lymphoma ( FL)Marginal Zone Lymphoma (MZL)
Incyte Corporation
Testing effectiveness (Phase 2)Study completedNCT02998476
What this trial is testing

Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Who this might be right for
Lymphoma
Incyte Corporation 60
Next Page